Stock Financial Ratios, Dividends, Split History

SALM / Salem Media Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)95.17
Enterprise Value ($M)344.74
Book Value ($M)230.47
Book Value / Share11.18
Price / Book0.41
NCAV ($M)-293.37
NCAV / Share-14.23
Price / NCAV-0.30
Share Statistics
Common Shares Outstanding2 5,553,696
Common Shares Outstanding 20,615,426
Weighted Average Number Of Shares Outstanding Basic 26,068,942
Weighted Average Number Of Diluted Shares Outstanding 26,435,757
Weighted Average Number Diluted Shares Outstanding Adjustment 366,815
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.04
Return on Equity (ROE)0.12
Identifiers and Descriptors
Central Index Key (CIK)1050606
Related CUSIPS

Split History

Stock splits are used by Salem Media Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Top Ranked Income Stocks to Buy for June 22nd

2018-06-22 zacks
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 22nd: (8-0)

Discovery (DISCA) Jumps: Stock Rises 6.6%

2018-06-18 zacks
Discovery, Inc. (DISCA - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $20.95 to $25.50 in the past one-month time frame. (3-0)

5 Top Stocks to Pull Through the June Swoon

2018-06-13 investorplace
June, generally, spells trouble for stocks. Trading is going to especially tight this month, thanks to the mid-term election. And if these weren’t enough, Trump is bent on severing trade ties. America’s biggest allies and trade partners are gearing up to fight the latest tariffs on steel and aluminum by targeting American products worth billions of dollars. Amid all these, mounting political instability in Italy and Spain, and tensions with North Korea are rippling through markets. (67-0)

Why Salem Media Group (SALM) Could Be a Top Value Stock Pick

2018-06-11 zacks
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends? (7-0)

The Zacks Analyst Blog Highlights: Kforce, Burlington Stores, Brookline Bancorp, Federated National Holding and Salem Media Group

2018-06-05 zacks
Chicago, IL – June 5, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Kforce Inc. (KFRC - Free Report) , Burlington Stores, Inc. (BURL - Free Report) , Brookline Bancorp, Inc. (BRKL - Free Report) , Federated National Holding Company (FNHC - Free Report) and Salem Media Group, Inc. (55-0)

CUSIP: 794093104